Soy Isoflavones in Preventing Head and Neck Cancer Recurrence in Patients With Stage I-IV Head and Neck Cancer Undergoing Surgery

NCT02007200 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-10-24

Study results available
· View outcomes & findings →

Summary

This phase II clinical trial studies how well soy isoflavones work in preventing head and neck cancer in patients with stage I-IV head and neck cancer undergoing surgery. Chemoprevention is the use of certain drugs to keep cancer from forming. The use of soy isoflavones may prevent head and neck cancer recurrence.

Conditions

  • Recurrent Hypopharyngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Squamous Cell Carcinoma
  • Recurrent Laryngeal Verrucous Carcinoma
  • Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
  • Recurrent Oral Cavity Verrucous Carcinoma
  • Recurrent Oropharyngeal Squamous Cell Carcinoma
  • Stage I Hypopharyngeal Squamous Cell Carcinoma
  • Stage I Laryngeal Squamous Cell Carcinoma
  • Stage I Laryngeal Verrucous Carcinoma
  • Stage I Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage I Oral Cavity Verrucous Carcinoma
  • Stage I Oropharyngeal Squamous Cell Carcinoma
  • Stage II Hypopharyngeal Squamous Cell Carcinoma
  • Stage II Laryngeal Squamous Cell Carcinoma
  • Stage II Laryngeal Verrucous Carcinoma
  • Stage II Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage II Oral Cavity Verrucous Carcinoma
  • Stage II Oropharyngeal Squamous Cell Carcinoma
  • Stage III Hypopharyngeal Squamous Cell Carcinoma
  • Stage III Laryngeal Squamous Cell Carcinoma
  • Stage III Laryngeal Verrucous Carcinoma
  • Stage III Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage III Oral Cavity Verrucous Carcinoma
  • Stage III Oropharyngeal Squamous Cell Carcinoma
  • Stage IV Hypopharyngeal Squamous Cell Carcinoma
  • Stage IVA Laryngeal Squamous Cell Carcinoma
  • Stage IVA Laryngeal Verrucous Carcinoma
  • Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma
  • Stage IVA Oral Cavity Verrucous Carcinoma
  • Stage IVA Oropharyngeal Squamous Cell Carcinoma
  • Tongue Carcinoma

Interventions

OTHER

Laboratory Biomarker Analysis

Correlative studies

DRUG

Soy Isoflavones

Given PO

OTHER

Survey Administration

Ancillary studies

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    lead NIH

Principal Investigators

  • Greg Wolf · University of Michigan Rogel Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
79 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-07-31
Primary Completion
2015-09-30
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02007200 on ClinicalTrials.gov